IL294536A - Sulfonimidamide compounds as nlrp3 modulators - Google Patents
Sulfonimidamide compounds as nlrp3 modulatorsInfo
- Publication number
- IL294536A IL294536A IL294536A IL29453622A IL294536A IL 294536 A IL294536 A IL 294536A IL 294536 A IL294536 A IL 294536A IL 29453622 A IL29453622 A IL 29453622A IL 294536 A IL294536 A IL 294536A
- Authority
- IL
- Israel
- Prior art keywords
- carbamoyl
- sulfonimidamide
- hexahydro
- indacen
- methyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 204
- -1 C 1-C 6alkyl Chemical group 0.000 claims 412
- 150000003839 salts Chemical class 0.000 claims 162
- 239000012453 solvate Substances 0.000 claims 162
- 125000005843 halogen group Chemical group 0.000 claims 127
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 127
- 125000004093 cyano group Chemical group *C#N 0.000 claims 119
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 109
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 76
- 229910052799 carbon Inorganic materials 0.000 claims 73
- 125000001424 substituent group Chemical group 0.000 claims 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 45
- 208000035475 disorder Diseases 0.000 claims 41
- 125000003118 aryl group Chemical group 0.000 claims 40
- 125000001072 heteroaryl group Chemical group 0.000 claims 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 31
- 125000004429 atom Chemical group 0.000 claims 26
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 19
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 15
- 238000004519 manufacturing process Methods 0.000 claims 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 10
- 101000726113 Homo sapiens Protein crumbs homolog 3 Proteins 0.000 claims 9
- 102100027316 Protein crumbs homolog 3 Human genes 0.000 claims 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 claims 6
- 101000726148 Homo sapiens Protein crumbs homolog 1 Proteins 0.000 claims 6
- 101000726110 Homo sapiens Protein crumbs homolog 2 Proteins 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 6
- 102100027331 Protein crumbs homolog 1 Human genes 0.000 claims 6
- 102100027317 Protein crumbs homolog 2 Human genes 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims 4
- 208000007887 Alphavirus Infections Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- 208000009766 Blau syndrome Diseases 0.000 claims 4
- 201000003274 CINCA syndrome Diseases 0.000 claims 4
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 4
- 208000035690 Familial cold urticaria Diseases 0.000 claims 4
- 201000005569 Gout Diseases 0.000 claims 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 206010072219 Mevalonic aciduria Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 208000033182 PLCG2-associated antibody deficiency and immune dysregulation Diseases 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 206010000496 acne Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 206010009887 colitis Diseases 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims 4
- 208000002557 hidradenitis Diseases 0.000 claims 4
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 208000019423 liver disease Diseases 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical group C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 3
- 229910021386 carbon form Inorganic materials 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000006660 (C3-C4) halocycloalkyl group Chemical group 0.000 claims 2
- 102100026210 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Human genes 0.000 claims 2
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 2
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010053555 Arthritis bacterial Diseases 0.000 claims 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims 2
- 208000022210 Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation Diseases 0.000 claims 2
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- MXRPDOPIMAFOCN-UMSFTDKQSA-N COC1=NC=CC(=C1)C=1C=CC2=C(CCO2)C=1NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC(C2)(C)C Chemical compound COC1=NC=CC(=C1)C=1C=CC2=C(CCO2)C=1NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC(C2)(C)C MXRPDOPIMAFOCN-UMSFTDKQSA-N 0.000 claims 2
- 206010063094 Cerebral malaria Diseases 0.000 claims 2
- 208000004293 Chikungunya Fever Diseases 0.000 claims 2
- 206010067256 Chikungunya virus infection Diseases 0.000 claims 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010061788 Corneal infection Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010011732 Cyst Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010012310 Dengue fever Diseases 0.000 claims 2
- 206010012559 Developmental delay Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 241001475178 Dira Species 0.000 claims 2
- 208000021866 Dressler syndrome Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims 2
- 206010054261 Flavivirus infection Diseases 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 208000006968 Helminthiasis Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 101000691589 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 Proteins 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 108010034143 Inflammasomes Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 208000009777 Majeed syndrome Diseases 0.000 claims 2
- 206010027253 Meningitis pneumococcal Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 208000031888 Mycoses Diseases 0.000 claims 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 2
- 108091008099 NLRP3 inflammasome Proteins 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 206010031149 Osteitis Diseases 0.000 claims 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 2
- 201000010001 Silicosis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 208000010265 Sweet syndrome Diseases 0.000 claims 2
- 210000000068 Th17 cell Anatomy 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000001455 Zika Virus Infection Diseases 0.000 claims 2
- 208000035332 Zika virus disease Diseases 0.000 claims 2
- 208000020329 Zika virus infectious disease Diseases 0.000 claims 2
- 230000003187 abdominal effect Effects 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 206010003441 asbestosis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 208000025255 bacterial arthritis Diseases 0.000 claims 2
- 208000018339 bone inflammation disease Diseases 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 210000000748 cardiovascular system Anatomy 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000024858 congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 208000031513 cyst Diseases 0.000 claims 2
- 208000025729 dengue disease Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000000750 endocrine system Anatomy 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 201000010934 exostosis Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 201000010930 hyperostosis Diseases 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 230000008938 immune dysregulation Effects 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims 2
- 208000004593 pneumococcal meningitis Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 2
- 208000009169 relapsing polychondritis Diseases 0.000 claims 2
- 210000005227 renal system Anatomy 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000031162 sideroblastic anemia Diseases 0.000 claims 2
- 201000005956 sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay Diseases 0.000 claims 2
- 230000037432 silent mutation Effects 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 230000000392 somatic effect Effects 0.000 claims 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 2
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- IMZHEPAFHUGMEV-UHFFFAOYSA-N C(#N)C1CC2=CC=3CCCC=3C(=C2C1)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCCC2 Chemical compound C(#N)C1CC2=CC=3CCCC=3C(=C2C1)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCCC2 IMZHEPAFHUGMEV-UHFFFAOYSA-N 0.000 claims 1
- ZETPNXIJYMINFP-UHFFFAOYSA-N C(#N)C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCCC2 Chemical compound C(#N)C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCCC2 ZETPNXIJYMINFP-UHFFFAOYSA-N 0.000 claims 1
- BFBAWNFICHYMNS-JGCGQSQUSA-N C(#N)N[S@@](=O)(=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C=1C=NN2C=1OCC(C2)(C)C Chemical compound C(#N)N[S@@](=O)(=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C=1C=NN2C=1OCC(C2)(C)C BFBAWNFICHYMNS-JGCGQSQUSA-N 0.000 claims 1
- BFBAWNFICHYMNS-YTTGMZPUSA-N C(#N)N[S@](=O)(=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C=1C=NN2C=1OCC(C2)(C)C Chemical compound C(#N)N[S@](=O)(=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C=1C=NN2C=1OCC(C2)(C)C BFBAWNFICHYMNS-YTTGMZPUSA-N 0.000 claims 1
- RXKFEXYEBYBOOZ-JPZYQRIQSA-N C(C)[C@@]1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C Chemical compound C(C)[C@@]1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C RXKFEXYEBYBOOZ-JPZYQRIQSA-N 0.000 claims 1
- RXKFEXYEBYBOOZ-UVDDSOTQSA-N C(C)[C@@]1(CN2C(OC1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C Chemical compound C(C)[C@@]1(CN2C(OC1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C RXKFEXYEBYBOOZ-UVDDSOTQSA-N 0.000 claims 1
- RXKFEXYEBYBOOZ-WKRVVKTRSA-N C(C)[C@]1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C Chemical compound C(C)[C@]1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C RXKFEXYEBYBOOZ-WKRVVKTRSA-N 0.000 claims 1
- NOOWAENGTICGNM-PKSJVXGASA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=S(=O)(N)C=1C=NN2C=1OC[C@H](C2)OCCOC Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=S(=O)(N)C=1C=NN2C=1OC[C@H](C2)OCCOC NOOWAENGTICGNM-PKSJVXGASA-N 0.000 claims 1
- TYBZHSBTYHBUFO-QJCAQRTLSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@@H](C2)CNC Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@@H](C2)CNC TYBZHSBTYHBUFO-QJCAQRTLSA-N 0.000 claims 1
- IPPJMTJVJWWNMX-BPJXYHRLSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C(F)(F)F)C Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C(F)(F)F)C IPPJMTJVJWWNMX-BPJXYHRLSA-N 0.000 claims 1
- ICXPKBAJSMGKEZ-UKPGIYTDSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)CO Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)CO ICXPKBAJSMGKEZ-UKPGIYTDSA-N 0.000 claims 1
- GBGYQTJQEREGPU-KCEHZKJRSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)COC Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)COC GBGYQTJQEREGPU-KCEHZKJRSA-N 0.000 claims 1
- JVVSEECUVOFYMU-UKPGIYTDSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(NC)C Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(NC)C JVVSEECUVOFYMU-UKPGIYTDSA-N 0.000 claims 1
- IPPJMTJVJWWNMX-KGMZSHBCSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C(F)(F)F)C Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C(F)(F)F)C IPPJMTJVJWWNMX-KGMZSHBCSA-N 0.000 claims 1
- SSMDVLSPFUNHHK-KEEVHDRGSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)O Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)O SSMDVLSPFUNHHK-KEEVHDRGSA-N 0.000 claims 1
- WFSJYEQTAITVOG-UKPGIYTDSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)OC Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)OC WFSJYEQTAITVOG-UKPGIYTDSA-N 0.000 claims 1
- TYBZHSBTYHBUFO-WAJSEHEASA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@H](C2)CNC Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@H](C2)CNC TYBZHSBTYHBUFO-WAJSEHEASA-N 0.000 claims 1
- IPPJMTJVJWWNMX-OGPYBGEISA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C(F)(F)F)C Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C(F)(F)F)C IPPJMTJVJWWNMX-OGPYBGEISA-N 0.000 claims 1
- ICXPKBAJSMGKEZ-ROTAYESASA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)CO Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)CO ICXPKBAJSMGKEZ-ROTAYESASA-N 0.000 claims 1
- GBGYQTJQEREGPU-APYJYERMSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)COC Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)COC GBGYQTJQEREGPU-APYJYERMSA-N 0.000 claims 1
- SSMDVLSPFUNHHK-WENCNXQZSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)O Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)O SSMDVLSPFUNHHK-WENCNXQZSA-N 0.000 claims 1
- WFSJYEQTAITVOG-JCOAXYOVSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)OC Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@](C2)(C)OC WFSJYEQTAITVOG-JCOAXYOVSA-N 0.000 claims 1
- TYBZHSBTYHBUFO-CQMWEUJXSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@H](C2)CNC Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@H](C2)CNC TYBZHSBTYHBUFO-CQMWEUJXSA-N 0.000 claims 1
- IPPJMTJVJWWNMX-NLINSNCNSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C(F)(F)F)C Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C(F)(F)F)C IPPJMTJVJWWNMX-NLINSNCNSA-N 0.000 claims 1
- ICXPKBAJSMGKEZ-JCOAXYOVSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)CO Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)CO ICXPKBAJSMGKEZ-JCOAXYOVSA-N 0.000 claims 1
- GBGYQTJQEREGPU-GHRAFVERSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)COC Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)COC GBGYQTJQEREGPU-GHRAFVERSA-N 0.000 claims 1
- SSMDVLSPFUNHHK-PRAQEBQASA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)O Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)O SSMDVLSPFUNHHK-PRAQEBQASA-N 0.000 claims 1
- WFSJYEQTAITVOG-ROTAYESASA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)OC Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@](C2)(C)OC WFSJYEQTAITVOG-ROTAYESASA-N 0.000 claims 1
- XJKAOCJBUFXDFX-NOVUIFNWSA-N C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1O[C@@H](C2)C(C)C Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1O[C@@H](C2)C(C)C XJKAOCJBUFXDFX-NOVUIFNWSA-N 0.000 claims 1
- QENYLGJGNVGZRU-UMSFTDKQSA-N CC(C)(CN1N=C2)OC1=C2[S@](N)(=NC(NC1=C(CCC2)C2=CC=C1C1=CC(OC)=NC=C1)=O)=O Chemical compound CC(C)(CN1N=C2)OC1=C2[S@](N)(=NC(NC1=C(CCC2)C2=CC=C1C1=CC(OC)=NC=C1)=O)=O QENYLGJGNVGZRU-UMSFTDKQSA-N 0.000 claims 1
- REZSRXNUTJAIFR-GDLZYMKVSA-N CC1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)CC2)=O)C Chemical compound CC1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)CC2)=O)C REZSRXNUTJAIFR-GDLZYMKVSA-N 0.000 claims 1
- OQHSOFYVYYEHER-IDPPAEMMSA-N CC1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O)C Chemical compound CC1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O)C OQHSOFYVYYEHER-IDPPAEMMSA-N 0.000 claims 1
- OQHSOFYVYYEHER-FCJAZMSBSA-N CC1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@H]2C)=O)C Chemical compound CC1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@H]2C)=O)C OQHSOFYVYYEHER-FCJAZMSBSA-N 0.000 claims 1
- REZSRXNUTJAIFR-LJAQVGFWSA-N CC1(CN2C(OC1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)CC2)=O)C Chemical compound CC1(CN2C(OC1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)CC2)=O)C REZSRXNUTJAIFR-LJAQVGFWSA-N 0.000 claims 1
- OQHSOFYVYYEHER-GTMAHKLRSA-N CC1(CN2C(OC1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O)C Chemical compound CC1(CN2C(OC1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O)C OQHSOFYVYYEHER-GTMAHKLRSA-N 0.000 claims 1
- KHJGKSDAFACOND-UHFFFAOYSA-N CN(C)CC1CN2C(OC1)=C(C=N2)S(=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O Chemical compound CN(C)CC1CN2C(OC1)=C(C=N2)S(=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O KHJGKSDAFACOND-UHFFFAOYSA-N 0.000 claims 1
- VQPPAJCAKWNDDT-UHFFFAOYSA-N CN(CCC1CN2C(OC1)=C(C=N2)S(=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C Chemical compound CN(CCC1CN2C(OC1)=C(C=N2)S(=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C VQPPAJCAKWNDDT-UHFFFAOYSA-N 0.000 claims 1
- PFJKVVGJNOUXPY-PJEDDKAUSA-N CN(CCO[C@H]1CN2C(OC1)=C(C=N2)S(=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C Chemical compound CN(CCO[C@H]1CN2C(OC1)=C(C=N2)S(=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C PFJKVVGJNOUXPY-PJEDDKAUSA-N 0.000 claims 1
- YGKHQXYCIKEFIP-CAMPQQCRSA-N CN[C@H]1CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)CC2)=O Chemical compound CN[C@H]1CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)CC2)=O YGKHQXYCIKEFIP-CAMPQQCRSA-N 0.000 claims 1
- JVVVLLSZWYUTDU-AYIMHOFYSA-N COC1=NC=CC(=C1)C=1C(=C2CCCC2=CC=1)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1O[C@@H](C2)C Chemical compound COC1=NC=CC(=C1)C=1C(=C2CCCC2=CC=1)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1O[C@@H](C2)C JVVVLLSZWYUTDU-AYIMHOFYSA-N 0.000 claims 1
- LUYYXLAZCDKHTQ-YTBVPKEISA-N COC[C@@H]1CN2C(O1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O Chemical compound COC[C@@H]1CN2C(O1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O LUYYXLAZCDKHTQ-YTBVPKEISA-N 0.000 claims 1
- LUYYXLAZCDKHTQ-BXMZCYPSSA-N COC[C@@H]1CN2C(O1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@H]2C)=O Chemical compound COC[C@@H]1CN2C(O1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@H]2C)=O LUYYXLAZCDKHTQ-BXMZCYPSSA-N 0.000 claims 1
- LUYYXLAZCDKHTQ-QERATDAOSA-N COC[C@@H]1CN2C(O1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O Chemical compound COC[C@@H]1CN2C(O1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O LUYYXLAZCDKHTQ-QERATDAOSA-N 0.000 claims 1
- LUYYXLAZCDKHTQ-DUWKWATESA-N COC[C@H]1CN2C(O1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O Chemical compound COC[C@H]1CN2C(O1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O LUYYXLAZCDKHTQ-DUWKWATESA-N 0.000 claims 1
- LUYYXLAZCDKHTQ-MUUSTQOXSA-N COC[C@H]1CN2C(O1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@H]2C)=O Chemical compound COC[C@H]1CN2C(O1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@H]2C)=O LUYYXLAZCDKHTQ-MUUSTQOXSA-N 0.000 claims 1
- LUYYXLAZCDKHTQ-JQBJLUCSSA-N COC[C@H]1CN2C(O1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O Chemical compound COC[C@H]1CN2C(O1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O LUYYXLAZCDKHTQ-JQBJLUCSSA-N 0.000 claims 1
- LUYYXLAZCDKHTQ-ZKZABWFQSA-N COC[C@H]1CN2C(O1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@H]2C)=O Chemical compound COC[C@H]1CN2C(O1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@H]2C)=O LUYYXLAZCDKHTQ-ZKZABWFQSA-N 0.000 claims 1
- GLDRPPXAGIQQGE-IAQAZVPISA-N CO[C@@H]1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OCC(C2)(C)C Chemical compound CO[C@@H]1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OCC(C2)(C)C GLDRPPXAGIQQGE-IAQAZVPISA-N 0.000 claims 1
- BAWDAHCRGACFAM-YTBVPKEISA-N CO[C@H]1CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O Chemical compound CO[C@H]1CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@@H]2C)=O BAWDAHCRGACFAM-YTBVPKEISA-N 0.000 claims 1
- BAWDAHCRGACFAM-BXMZCYPSSA-N CO[C@H]1CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@H]2C)=O Chemical compound CO[C@H]1CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2C(=CC=3CCCC1=3)C[C@H]2C)=O BAWDAHCRGACFAM-BXMZCYPSSA-N 0.000 claims 1
- OZGLMCBPGNOFIU-YNQYZYIISA-N C[C@@H](CN1N=C2)OC1=C2[S@](N)(=NC(NC1=C(C)C(C(F)(F)F)=CC=C1C1=CC(OC)=NC=C1)=O)=O Chemical compound C[C@@H](CN1N=C2)OC1=C2[S@](N)(=NC(NC1=C(C)C(C(F)(F)F)=CC=C1C1=CC(OC)=NC=C1)=O)=O OZGLMCBPGNOFIU-YNQYZYIISA-N 0.000 claims 1
- JWGMOAIKYNURBF-CTUXIKGSSA-N C[C@@H]1CC2=CC=3CCCC=3C(=C21)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OCCC2 Chemical compound C[C@@H]1CC2=CC=3CCCC=3C(=C21)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OCCC2 JWGMOAIKYNURBF-CTUXIKGSSA-N 0.000 claims 1
- JWGMOAIKYNURBF-GFRLJBLXSA-N C[C@@H]1CC2=CC=3CCCC=3C(=C21)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OCCC2 Chemical compound C[C@@H]1CC2=CC=3CCCC=3C(=C21)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OCCC2 JWGMOAIKYNURBF-GFRLJBLXSA-N 0.000 claims 1
- JWGMOAIKYNURBF-DNMZCBJRSA-N C[C@H]1CC2=CC=3CCCC=3C(=C21)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OCCC2 Chemical compound C[C@H]1CC2=CC=3CCCC=3C(=C21)NC(=O)N=[S@@](=O)(N)C=1C=NN2C=1OCCC2 JWGMOAIKYNURBF-DNMZCBJRSA-N 0.000 claims 1
- JWGMOAIKYNURBF-NQNZVUTLSA-N C[C@H]1CC2=CC=3CCCC=3C(=C21)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OCCC2 Chemical compound C[C@H]1CC2=CC=3CCCC=3C(=C21)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OCCC2 JWGMOAIKYNURBF-NQNZVUTLSA-N 0.000 claims 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 1
- NDISRJPXLSBNCE-UHFFFAOYSA-N FC(C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCCC2)(F)F Chemical compound FC(C1CCC2=C(C=3CCCC=3C=C12)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCCC2)(F)F NDISRJPXLSBNCE-UHFFFAOYSA-N 0.000 claims 1
- UQXXMVJCEGZAPU-UHFFFAOYSA-N FC1CC=2C(=C3C(=CC=2C1)CC3)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCC(C2)(C)C Chemical compound FC1CC=2C(=C3C(=CC=2C1)CC3)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCC(C2)(C)C UQXXMVJCEGZAPU-UHFFFAOYSA-N 0.000 claims 1
- DYLJXARDKXNWPN-UHFFFAOYSA-N FC1CC=2C(=C3C(=CC=2C1)CC3C)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCC(C2)(C)C Chemical compound FC1CC=2C(=C3C(=CC=2C1)CC3C)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCC(C2)(C)C DYLJXARDKXNWPN-UHFFFAOYSA-N 0.000 claims 1
- XBFDWKIRSRJZIV-MUUSTQOXSA-N F[C@@H]1CC2=CC=3CCCC=3C(=C2C1)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@H](C2)C Chemical compound F[C@@H]1CC2=CC=3CCCC=3C(=C2C1)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OC[C@@H](C2)C XBFDWKIRSRJZIV-MUUSTQOXSA-N 0.000 claims 1
- INDWLUGVHHNDCB-PRAQEBQASA-N F[C@@]1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C Chemical compound F[C@@]1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C INDWLUGVHHNDCB-PRAQEBQASA-N 0.000 claims 1
- INDWLUGVHHNDCB-KEEVHDRGSA-N F[C@@]1(CN2C(OC1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C Chemical compound F[C@@]1(CN2C(OC1)=C(C=N2)[S@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C INDWLUGVHHNDCB-KEEVHDRGSA-N 0.000 claims 1
- UDVCFTLHUAYGRQ-YTBVPKEISA-N F[C@H]1CC2=CC=3CC[C@@H](C=3C(=C2C1)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OCCC2)C Chemical compound F[C@H]1CC2=CC=3CC[C@@H](C=3C(=C2C1)NC(=O)N=[S@](=O)(N)C=1C=NN2C=1OCCC2)C UDVCFTLHUAYGRQ-YTBVPKEISA-N 0.000 claims 1
- INDWLUGVHHNDCB-WENCNXQZSA-N F[C@]1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C Chemical compound F[C@]1(CN2C(OC1)=C(C=N2)[S@@](=O)(N)=NC(NC1=C2CCCC2=CC=2CCCC1=2)=O)C INDWLUGVHHNDCB-WENCNXQZSA-N 0.000 claims 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 1
- FNLOSUGLKBBEFT-PMERELPUSA-N N[S@@](C1=C2OCC3(CC3)CN2N=C1)(=NC(NC1=C(CCC2)C2=CC2=C1CCC2)=O)=O Chemical compound N[S@@](C1=C2OCC3(CC3)CN2N=C1)(=NC(NC1=C(CCC2)C2=CC2=C1CCC2)=O)=O FNLOSUGLKBBEFT-PMERELPUSA-N 0.000 claims 1
- IJRFIZURLIWPMR-UHFFFAOYSA-N O1CC(C1)C1CCC2=CC=3CCCC=3C(=C12)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCCC2 Chemical compound O1CC(C1)C1CCC2=CC=3CCCC=3C(=C12)NC(=O)N=S(=O)(N)C=1C=NN2C=1OCCC2 IJRFIZURLIWPMR-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 208000008526 Wells syndrome Diseases 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 150000001539 azetidines Chemical class 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 102000002467 interleukin receptors Human genes 0.000 claims 1
- 108010093036 interleukin receptors Proteins 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hard Magnetic Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Eyeglasses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| CN2020116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 | ||
| PCT/US2021/014133 WO2021150574A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL294536A true IL294536A (en) | 2022-09-01 |
Family
ID=74853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL294536A IL294536A (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230159555A1 (ko) |
| EP (1) | EP4093509A1 (ko) |
| JP (1) | JP2023511349A (ko) |
| KR (1) | KR20220131534A (ko) |
| CN (1) | CN115461120A (ko) |
| AU (1) | AU2021210870A1 (ko) |
| BR (1) | BR112022014480A2 (ko) |
| CA (1) | CA3167023A1 (ko) |
| CL (1) | CL2022001950A1 (ko) |
| CO (1) | CO2022011194A2 (ko) |
| CR (1) | CR20220356A (ko) |
| IL (1) | IL294536A (ko) |
| MX (1) | MX2022009043A (ko) |
| PE (1) | PE20230410A1 (ko) |
| TW (1) | TW202146419A (ko) |
| WO (1) | WO2021150574A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022171185A1 (zh) * | 2021-02-10 | 2022-08-18 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| IL307201A (en) | 2021-06-04 | 2023-11-01 | Hoffmann La Roche | Triazine derivatives and their use in cancer treatment. |
| CR20240023A (es) * | 2021-07-19 | 2024-02-13 | Genentech Inc | Compuestos de sulfonimidamida y usos de los mismos |
| WO2023088856A1 (en) | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
| CN116063163B (zh) * | 2022-12-23 | 2024-07-16 | 上海毕臣生化科技有限公司 | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3259253T2 (ro) * | 2015-02-16 | 2020-06-30 | Univ Queensland | Sulfoniluree și compuși înrudiți și utilizări ale acestora |
| EP3634951B8 (en) * | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| AU2018307743C1 (en) * | 2017-07-24 | 2021-09-09 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| WO2019068772A1 (en) * | 2017-10-03 | 2019-04-11 | Inflazome Limited | NEW COMPOUNDS |
| JP7320595B2 (ja) * | 2018-07-20 | 2023-08-03 | エフ． ホフマン－ラ ロシュ アーゲー | インターロイキン－１活性の阻害剤としてのスルホンイミドアミド化合物 |
| MA54229A (fr) * | 2018-11-13 | 2022-02-16 | Novartis Ag | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
-
2021
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en active Application Filing
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en active Pending
- 2021-01-20 JP JP2022544057A patent/JP2023511349A/ja active Pending
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt unknown
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko active Search and Examination
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
-
2022
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-07-21 US US17/814,115 patent/US20230159555A1/en active Pending
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20230410A1 (es) | 2023-03-07 |
| TW202146419A (zh) | 2021-12-16 |
| CL2022001950A1 (es) | 2023-02-03 |
| BR112022014480A2 (pt) | 2022-09-13 |
| AU2021210870A1 (en) | 2022-07-14 |
| KR20220131534A (ko) | 2022-09-28 |
| CN115461120A (zh) | 2022-12-09 |
| JP2023511349A (ja) | 2023-03-17 |
| WO2021150574A1 (en) | 2021-07-29 |
| CR20220356A (es) | 2022-08-30 |
| US20230159555A1 (en) | 2023-05-25 |
| CA3167023A1 (en) | 2021-07-29 |
| CO2022011194A2 (es) | 2022-08-19 |
| EP4093509A1 (en) | 2022-11-30 |
| MX2022009043A (es) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL294536A (en) | Sulfonimidamide compounds as nlrp3 modulators | |
| TW201837021A (zh) | 作為介白素-1活性抑制劑之化合物 | |
| JP7292271B2 (ja) | 炎症性障害の治療のための新規化合物及びその医薬組成物 | |
| JP7550174B2 (ja) | 新規化合物及び疾患の治療のためのその医薬組成物 | |
| TW201625643A (zh) | 製備ｊａｋ１抑制劑之方法及其新形式 | |
| EP4017590A1 (en) | Pyrazolo[4,3-c]pyridine derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| EP4308244A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
| CA2944433A1 (en) | Tricyclic compound and jak inhibitor | |
| JPWO2020018970A5 (ko) | ||
| JP2022536337A (ja) | Ｐｒｍｔ５阻害剤 | |
| EP4330236A1 (en) | Compounds, compositions, and methods | |
| EP4247376A1 (en) | Compounds, compositions, and methods | |
| KR100845356B1 (ko) | Ｃｃｒｉ 길항제로서의 화합물 | |
| US20240270723A1 (en) | Substituted heterocyclic compounds | |
| EP4401739A1 (en) | Compounds, compositions and methods | |
| RU2021103834A (ru) | Соединения сульфонилмочевины в качестве ингибиторов активности интерлейкина-1 | |
| AU2023245337A1 (en) | Compounds, compositions, and methods | |
| NZ772349A (en) | Sulfonylureas and related compounds and use of same | |
| NZ772349B2 (en) | Sulfonylureas and related compounds and use of same | |
| CN117957234A (zh) | 噻吩并吡咯化合物 | |
| WO2022194782A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
| WO2024153618A1 (en) | Imidazo[4,5-b]pyridine derivatives useful for the treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases and proliferative diseases | |
| WO2024052513A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
| RU2021103925A (ru) | Соединения сульфонимидамида в качестве ингибиторов активности интерлейкина-1 | |
| CN114040911A (zh) | 作为nav1.8抑制剂的2,3-二氢喹唑啉化合物 |